- Home
- BTX vs MIRM Comparison
BTX vs MIRM Comparison
Compare BTX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTX
- MIRM
- Stock Information
- Founded
- BTX N/A
- MIRM 2018
- Country
- BTX United States
- MIRM United States
- Employees
- BTX N/A
- MIRM N/A
- Industry
- BTX
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- BTX
- MIRM Health Care
- Exchange
- BTX Nasdaq
- MIRM Nasdaq
- Market Cap
- BTX 1.5B
- MIRM 2.5B
- IPO Year
- BTX N/A
- MIRM 2019
- Fundamental
- Price
- BTX $7.41
- MIRM $50.30
- Analyst Decision
- BTX
- MIRM Strong Buy
- Analyst Count
- BTX 0
- MIRM 9
- Target Price
- BTX N/A
- MIRM $66.22
- AVG Volume (30 Days)
- BTX 766.9K
- MIRM 468.1K
- Earning Date
- BTX 08-15-2025
- MIRM 08-06-2025
- Dividend Yield
- BTX 13.99%
- MIRM N/A
- EPS Growth
- BTX N/A
- MIRM N/A
- EPS
- BTX N/A
- MIRM N/A
- Revenue
- BTX N/A
- MIRM $379,251,000.00
- Revenue This Year
- BTX N/A
- MIRM $35.83
- Revenue Next Year
- BTX N/A
- MIRM $16.83
- P/E Ratio
- BTX N/A
- MIRM N/A
- Revenue Growth
- BTX N/A
- MIRM 69.31
- 52 Week Low
- BTX $5.10
- MIRM $33.52
- 52 Week High
- BTX $8.31
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- BTX N/A
- MIRM 59.09
- Support Level
- BTX N/A
- MIRM $47.89
- Resistance Level
- BTX N/A
- MIRM $51.93
- Average True Range (ATR)
- BTX 0.00
- MIRM 1.49
- MACD
- BTX 0.00
- MIRM -0.25
- Stochastic Oscillator
- BTX 0.00
- MIRM 59.65
About BTX BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.